X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 16c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of $0.04, $0.16 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $28.81 million versus the consensus estimate of $12.03 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Doncasters Group IPO expected to price at top of range
• EG Group Is Said To Confidentially File For $1 Billion UU IPO - Bloomberg